This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administred to a Hepatocellular carcinoma (HCC) patient. Futher the invention is directed to in-vitro methods for identifying mutated-type KRAS or NRAS gene in HCC patient and kits thereof.本發明係關於定義為KRAS或NRAS基因之一或多種生物標記之用途,其用於預測待投與至肝細胞腫瘤(HCC)病患之MEK蛋白激酶抑制劑及/或索拉非尼(Sorafenib)或瑞戈非尼(Regorafenib)之醫藥功效或臨床反應。本發明進一步關於用於鑑別HCC病患中之突變型KRAS或NRAS基因之活體外方法及其套組。
